Skip to main content
. 2001 May 15;21(10):3628–3638. doi: 10.1523/JNEUROSCI.21-10-03628.2001

Fig. 2.

Fig. 2.

Dopamine agonist effects on eIPSC amplitude.A, Counterclockwise from top left, Application of dopamine (20 μm) in the presence of a D1 antagonist (10 μm SCH-23390) produced a pure depression of eIPSC amplitude (gray triangles;n = 3), whereas application of dopamine in the presence of a D2 antagonist (10 μm sulpiride or raclopride; n = 12) produced only a slight increase in eIPSC amplitude. B, Top, Representative traces showing that application of a D2 agonist (quinpirole 10 μm; n = 8) produced a pure decrease in eIPSC amplitude. Bottom, Mean and SEM group data showing that the D2 agonist reduced the average eIPSC amplitude (black triangles) and that this effect was blocked by coapplication of a D2 antagonist (gray triangles). C, Top, Representative traces showing that application of a D1 agonist (10 μm SKF-81297; n = 12) produced a pure increase in eIPSC amplitude. Bottom, Mean and SEM group data showing that the D1 agonist increased the average eIPSC amplitude (black squares) and that this effect was blocked by coapplication of a D1 antagonist (gray triangles). D, The dopamine effect on eIPSCs (gray triangles; n = 20) is similar to the linear sum (black circles) of the effect of the D1 agonist and D2 agonist (graphs shown in B andC) aligned to the time of drug offset.